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Delta-like ligand 4 (DLL4) expression in endothelial cells is 
intimately associated with angiogenic sprouting and vascular 
remodeling, but the precise mechanism of transcriptional 
regulation of DLL4 remains incompletely understood. Here, 
we showed that LIM-domain binding protein 2 (LDB2) plays 
an important role in regulating basal DLL4 and VEGF-induced 
DLL4 expression. Knockdown of LDB2 using siRNA enhanced 
endothelial sprouting and tubular network formation in vitro. 
Injection of ldb2-morpholino resulted in defective development 
of intersegmental vessels in zebrafish. Reduction or over-
expression of LDB2 in endothelial cells decreased or increased 
DLL4 expression. LDB2 regulated DLL4 promoter activity by 
binding to its promoter region and the same promoter region 
was occupied and regulated by the LMO2/TAL1/GATA2 
complex. Interestingly, LDB2 also mediated VEGF-induced 
DLL4 expression in endothelial cells. The regulation of DLL4 
by the LDB2 complex provides a novel mechanism of DLL4 
transcriptional control that may be exploited to develop 
therapeutics for aberrant vascular remodeling. [BMB Reports 
2018; 51(1): 21-26]
INTRODUCTION
Well-coordinated sprouting angiogenesis is essential for 
formation of functional vascular networks during development 
and adulthood. DLL4 plays a critical role in endothelial 
sprouting and vascular remodeling relevant in physiologic and 
pathologic angiogenesis (1, 2). DLL4 expression is mainly 
detected in the restricted region of nascent vessels, particularly 
in tip cells, which is associated with VEGF signaling. VEGF 
induces the tip cell phenotype and DLL4 expression (3, 4) and 
triggers Notch signaling in adjacent cells, and this, in turn, 
attenuates VEGF signaling and inhibits tip cell behavior (5, 6), 
thereby balancing vessel sprouting. Gene inactivation or 
pharmacological inhibition of DLL4 or Notch results in 
excessive sprouting with an increased number of tip cells at 
the vascular front and hyperdense vascular networks (3, 4, 6). 
Despite the central role of DLL4 in vascular remodeling and 
angiogenesis, the precise transcriptional regulatory mechanism 
of DLL4 is less well defined. 
LIM-domain binding proteins (LDBs) were initially identified 
as co-factors for LIM-homeodomain (LHX) transcription factors 
and LIM-only (LMO) proteins (7), which play critical roles in 
cell fate determination, differentiation, and tissue development 
(8, 9). LDBs were also shown to interact with other trans-
cription factors, including GATA, bHLH, and Otx family 
members (10, 11). The LDB family is composed of two members, 
LDB1 and LDB2, which are highly homologous in two well 
conserved domains: an amino-terminal homodimerization 
domain (DD) and a carboxyl-terminal LIM interaction domain 
(LID) (9). These domains play important roles in mediating 
transcription through higher-order transcription complexes 
containing TAL1/E47/GATA1/LMO2/LDB. Of particular interest 
is that LDB1 mediates long-range promoter-enhancer interactions 
through these multimeric complexes, which regulate erythroid 
gene transcription (11, 12). Although the roles of LDB1 in 
diverse developmental processes, including erythroid differen-
tiation, are relatively well established, the function of LDB2 
has not yet been clearly determined. In this study, we 
determined that LDB2 plays a key role in angiogenic sprouting 
by regulating DLL4 through higher-order transcription com-
plexes in endothelial cells. 
RESULTS
Depletion of LDB2 in endothelial cells leads to aberrant 
tubular network formation and endothelial sprouting
To identify transcription factors that are critical for the 
angiogenic activity of endothelial cells, we screened trans-
cription factors whose expressions were significantly altered 
during endothelial progenitor cell (EPC) differentiation from a 
BMB Rep. 2018; 51(1): 21-26
www.bmbreports.org
LDB2 regulates DLL4 expression in ECs
Hyun-Jung Choi, et al.
22 BMB Reports http://bmbreports.org
Fig. 1. Depletion of LDB2 in endothelial cells results in abnormal 
endothelial sprouting. (A-C) HUVECs were transfected with control 
or LDB2 siRNA (80 nM) and 3-D fibrin gel assay was performed. 
(A) Representative images of sprouting from HUVECs transfected 
with indicating siRNA (80 nM). Sacale bars: 100 μm (B and C) 
Quantification of sprouts in a 3-D-fibrin gel assay. Beads coated 
with HUVECs were seeded and cultured in fibrin gel for 5 days. 
(n = 4; 15 beads were assayed in each experiment). (D-G) Control
morpholino (D and F) or ldb2 morpholino (E and G) was micro-
injected at one cell stage of zebrafish and pictures were taken at 
75 hpf to examine the vessel development. High magnification of 
control embryo's trunk region (F) showing no abnormality and ldb2
morpholino-injected embryo's trunk region (G) showing aberrant 
development of intersegmental vesseles. (H-K) Control or ldb2 
morpholino of 1.5 ng, 4.5 ng and 5 ng was injected. ldb2 morpho-
lino-injected embryos show disorganized and hyper-branched
intersegmental vessels (I-K, red rounds and arrows). Error bars 
represent mean ± SD. ***P ＜ 0.001. Student’s t test.
Fig. 2. LDB2 regulates transcription of DLL4 in endothelial cells. 
(A, B) HUVECs were transfected with control or LDB2 siRNA (80 
nM) and DLL4 protein and transcript level was determined by 
Western blot analysis (A) and RT-PCR (B). (C) Luciferase activity 
in cells co-transfected with LDB2 siRNA and luciferase reporter 
containing human DLL4 promoter (−4.0 kb). (D) HUVECs were 
transfected pCMV2-FLAG mock (1 μg) or pCMV2-FLAG-LDB2 
vector (1 μg) and DLL4 proteins level was determined by 
Western blot analysis. (E) HUVECs were transfected with the 
DLL4 promoter- luciferase reporter vector along with increased 
amount of LDB2- expression vector. Luciferase activity was 
measured. Each experiment was repeated at least 3 times. Error bars 
represent mean ± standard deviation (SD). **P ＜ 0.01; ***P ＜
0.001. Student’s t test.
microarray analysis (GEO accession number GSE12891). The 
mRNA of LDB2 was dramatically induced during EPC differen-
tiation, whereas mRNA expression of LDB1, a homologue, 
was not significantly changed (Supplementary Fig. 1). To 
address the role of LDB2 in endothelial cells, we performed 
tubular network formation assay on Matrigel with endothelial 
cells transfected with siRNA targeting LDB2 (Supplementary 
Fig. 2A-C). Number of meshes formed on Matrigel increased in 
LDB2-deficient endothelial cells when compared to control 
cells (Supplementary Fig. 2B and C) A 3D-fibrin-gel bead assay 
with LDB2-deficient endothelial cells displayed more sprouting, 
and the length of sprouts were increased compared to control 
cells (Fig. 1A-C). To investigate the role of ldb2 during 
angiogenesis in vivo, we knock-downed ldb2 gene expression 
using morpholino and observed intersegmental trunk vessels 
(ISV) in transgenic zebrafish embryos with fluorescent blood 
vessels (refered to as Tg(flk-1:egfp) embryos). At 72 hpf, 
control MO-injected embryos showed no apparent vascular 
abnormality (Fig. 1D and F, Control MO). By contrast, ldb2 
MO-injected Tg(flk-1:egfp) embryos displayed 
vessel-branching defects (Fig. 1E and G, ldb2 MO). 
High-magnification images confirmed that ISVs of ldb2 
MO-injected embryo was disorganized and hyper-branched at 
this stage in a dose- dependent manner (Fig. 1H-K).
LDB2 regulates transcription of DLL4 in endothelial cells
The increased sprouting and hyper-dense network formation 
by LDB2-knockdowned endothelial cells is reminiscent of the 
behavior of DLL4-deficient endothelial cells (13). To elucidate 
the relationship between DLL4 and LDB2 in endothelial cells, 
DLL4 protein levels were measured in LDB2-deficient 
endothelial cells. The level of DLL4 protein expression was 
significantly reduced (Fig. 2A). Because LDB2 is a transcription 
co-factor, we examined transcription of DLL4 after LDB2 
knockdown in HUVECs and found that the transcript level and 
promoter activity of DLL4 decreased (Fig. 2B and C). Con-
versely, DLL4 expression was increased when LDB2 was 
overexpressed in HUVECs (Fig. 2D). DLL4 promoter activity 
was also increased with LDB2 expression in a dose-dependent 
manner, although the induction level was relatively low (Fig. 
2E). This moderate change may be attributed to the fact that 
LDB2 is a transcription co-factor, which requires other 
transcription factors for full induction of transcription of a 
target promoter. 
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Fig. 3. LDB2 regulates DLL4 promoter activity via TAL1 and GATA2
binding on DLL4 promoter. (A) The human DLL4 promoter region 
containing the E-box-GATA2 element (binding sites for TAL1 and 
GATA2) is depicted. Wild-type (W) and mutant (M) sequences are 
shown. The point mutations are underlined. (B) HUVECs were trans-
fected with wild-type or mutant DLL4 promoters fused to a luciferase
reporter along with a pCMV2-FLAG or pCMV2-FLAG-LDB2 expression
vector. Luciferase activity was measured 24 h after transfection. 
(C) HUVECs were transfected with a mock vector, an LDB2 
vector, or an LDB2 (L2), LMO2 (LM2), GATA2 (G2), E47, and 
TAL1 (T1) vector along with a DLL4 promoter-luciferase reporter. 
The total amount of transfected DNA was adjusted to 4 μg. (D-F) 
DLL4 transcripts were measured in HUVECs transfected with 
indicated siRNA by qRT-PCR. Error bars represent mean ± SD. 
**P ＜ 0.01, ***P ＜ 0.001 by Student’s t test. (G) Primers 
corresponding to the region that encompasses the E-box-GATA2
element of the DLL4 promoter are denoted as A and primers 
corresponding to the DLL4 coding region are denoted as B for 
CHIP analysis. (H) HUVECs were transfected with the pCMV2-FLAG
mock vector or the pCMV2-FLAG-LDB2 vector, and FLAG-LDB2 
was immunoprecipitated with an anti-FLAG antibody. Co-immuno-
precipitated and input DNAs were amplified with the primers 
indicated in G. (I) Endogenous TAL1 and GATA2 were immuno-
precipitated in HUVECs with anti-TAL1 and anti-GATA2 antibodies, 
respectively. Co-immunoprecipitated and input DNAs were amplified 
with primers indicated in G. Each experiment was repeated at 
least 3 times. 
Fig. 4. LDB2 mediates VEGF-induced DLL4 expression. (A) The 
dominant negative form of LDB2 (LDB2DN, a.a. 215-373) was 
depicted. LDB2FL, full length form of LDB2; NLS, nuclear locali-
zation sequence; LID, LIM-interacting domain. (B and C) HUVECs 
were transfected with pCMV2-FLAG or pCMV2-FLAG-LDB2DN and 
treated with VEGF (50 ng/ml). (B) mRNA of DLL4 was analyzed 
by RT-PCR. (C) Expression of DLL4 and LDB2 protein was detected
by western blotting. (D) HUVECs transfected with mock vector or 
with LDB2 vector and with the DLL4 promoter-luciferase reporter 
were treated with VEGF. Luciferase activity was determined. (E) 
CHIP assays were performed with lysates from HUVECs transfected
with mock vector or with the LDB2DN expression vector. Endo-
genous TAL1 was immunoprecipitated 1 h after VEGF treatment. 
Each experiment was repeated at least 3 times. Error bars re-
present mean ± SD. **P ＜ 0.01, ***P ＜ 0.001 by Student’s t test.
LDB2 regulates DLL4 transcriptionally through the 
multimeric complex consisting of LMO2, TAL1, and GATA2 
onto DLL4 promoter
LDB2 regulates genes by interacting with transcriptional 
factors that directly bind to DNA, and several transcription 
factors have been identified as binding partners of LDB 
proteins. LDB proteins are known to bind TAL1/GATA 
transcription factors, and this interaction is mediated by 
LMO2. Interestingly, TAL1/GATA binding sites were found 
−1.9 kb from the DLL4 promoter region, and this organi-
zation is highly conserved in mice and humans (Fig. 3A and 
Supplementary Fig. 3). Activation of the mouse DLL4 promoter 
by LDB2 protein was suppressed when the promoter region 
containing TAL1/GATA binding sites was deleted (Supplementary 
Fig. 3). Site-directed mutagenesis of these sites also suppressed 
LDB2-induced and basal DLL4 promoter activity (Fig. 3B). 
To determine whether this transcription factor complex 
regulates transcription from the DLL4 promoter, the components 
of the complex were overexpressed in HUVECs along with the 
DLL4 promoter fused to luciferases. The promoter activity of 
DLL4 was significantly enhanced by cotransfection with TAL1, 
E47, GATA2, LMO2, and LDB2 (Fig. 3C). In accordance with 
this, DLL4 transcription was reduced when TAL1, GATA2, or 
LMO2 was knocked-down by siRNA in HUVECs (Fig. 3D-F). 
These results suggest that the TAL1/E47/GATA2/LMO2 complex 
bound by LDB2 may play a significant role in transcriptional 
regulation of DLL4 in endothelial cells. To further elucidate the 
transcriptional regulation of DLL4 by LDB2, we performed chro-
matin immunoprecipitation in LDB2-overexpressing HUVECs. 
LDB2-FLAG was immunoprecipitated at the TAL1 and GATA2 
binding sites of the DLL4 promoter (Fig. 3G and H). 
Endogenous TAL1 and GATA2 were also detected at the same 
promoter region (Fig. 3I). 
LDB2 mediates VEGF-induced DLL4 expression
It is well known that VEGF induces DLL4 transcriptionally in 
endothelial cells, and thereby restricts tip cell formation in 
adjacent cells. To determine whether DLL4 induction by VEGF 
is regulated by LDB2 in endothelial cells, HUVECs transfected 
with a dominant negative form of LDB2 (LDB2 DN; the 
LDB2 regulates DLL4 expression in ECs
Hyun-Jung Choi, et al.
24 BMB Reports http://bmbreports.org
dimerization-domain deletion mutant) (Fig. 4A). Transcription 
of DLL4 was induced by VEGF in control cells, and this 
induction of DLL4 mRNA by VEGF was suppressed in LDB2 
DN-expressing cells (Fig. 4B). Expression of DLL4 protein was 
also induced by VEGF. Similar to DLL4 expression, 
endogenous LDB2 protein was increased by VEGF treatment. 
However, the induction of expression of DLL4 protein by 
VEGF was inhibited by LDB2 DN (Fig. 4C). The reporter 
activity of the DLL4 promoter was increased by VEGF 
treatment, and this was further enhanced by LDB2 expression 
(Fig. 4D). Moreover, chromatin immunoprecipitation results 
revealed that binding of TAL1 to the DLL4 promoter region 
was also increased by VEGF treatment and this increase was 
suppressed by expression of LDB2 DN (Fig. 4E). These results 
suggest that LDB2 is involved in VEGF induction of DLL4 
through its oligomerization.
DISCUSSION
LDB transcription co-factor proteins have been suggested to be 
important for the regulation of cell selection and cell fate 
determination via their interactions with LIM domain containing 
transcription factors (7, 14). In this study, we showed that LDB2 
is expressed in endothelial cells and that it plays a unique role 
in vascular remodeling by regulating expression of DLL4. 
Despite the incomparable role of DLL4 expression on vascular 
morphogenesis, transcriptional regulation of DLL4 in endothelial 
cells has remained largely unclear. A few transcription factors, 
including Wnt signaling effector, β-catenin, and FOXC trans-
cription factors that regulate DLL4 expression in endothelial 
cells have been identified (15-17), but these studies did not 
provide direct evidence of their roles in VEGF-induced DLL4 
expression. The current study provides a new insight into the 
transcriptional regulation of DLL4 expression and shows that 
an LDB2-containing higher-order transcriptional complex 
mediates basal and VEGF-induced DLL4 expression. ETS 
transcription factors have also been identified as regulators of 
DLL4 expression and they primarily function during arterial 
specification (18). SOXF transcription factors and the 
RBPJ/NICD complex also regulate DLL4 transcription during 
arterial specification (19). Because these studies focused on 
regulation of arterial-specific DLL4 expression during 
development, they did not evaluate regulation of DLL4 
expression during endothelial sprouting. Further, the 
regulatory elements bound by these factors are in intron 3 of 
DLL4 rather than in the promoter sites identified in this study. 
Thus, it is likely that the mechanisms regulating DLL4 
expression during arterial specification and during angiogenic 
sprouting are distinct. 
TAL1, a transcription factor initially identified in human 
acute T-cell leukemia, has been shown to be involved in both 
developmental and postnatal angiogenesis (20, 21). TAL1 
deletion mutant mice showed defective yolk sac angiogenesis 
due to the defect in Tal1-/- endothelial cells. TAL knockdown 
in HUVECs resulted in defective cell migration, which led to a 
lack of tubular network formation on Matrigel (22). VE- 
cadherin has been identified as a target of the TAL1 complex 
in endothelial cells (23). Deletion of LMO2, which interacts 
with LDB2 and TAL1/GATA2, also caused a severe angiogenesis 
defect in mouse embryos (24). The vascular defects caused by 
these genetic deficiencies were not due to impaired formation 
of the primitive vascular plexus, but rather were due to defects 
in subsequent angiogenic remodeling processes. The results 
from these studies and our study suggest that misregulated 
expression of DLL4 by the lack of these transcription factors 
may be the cause of the abnormal vascular remodeling 
observed in these mutant mice. Furthermore, LDB2 was 
identified as an upregulated gene during the morphogenic 
stages of angiogenesis in a chick chorioallantoic membrane 
assay (25), and LDB2 expression in blood vessels in the lungs 
of mice was confirmed (25). There was no significant vascular 
phenotype in LDB2 mutant mouse embryos presumably 
because the homologue LDB1 may compensate for LDB2. 
However, more detailed investigations on blood vessel 
development in mutant mice and further elucidation of the 
role of LDB2 in pathological angiogenesis is required. 
In conclusion, this study suggests that LDB2 plays a role in 
endothelial sprouting by regulating DLL4 expression via an 
oligomeric complex and that manipulation of the LDB2 
complex could be exploited for the development of therapeutic 
strategies to inhibit aberrant angiogenesis. 
MATERIALS AND METHODS
Cell cultures
Primary human umbilical vein endothelial cells (HUVEC) were 
purchased from Lonza Inc. and used between passage 4 and 8. 
Endothelial cells were cultured in gelatin-coated plates in 
Medium 199 (Hyclone) containing 20% FBS (Lonza), 3 ng/ml 
basic-FGF (R&D System), 5 units/ml heparin (Sigma), and 1% 
penicillin-streptomycin (Gibco).
Tube formation assay and in vitro morphogenesis on 2-D 
Matrigel
Tube formation was assayed as previously described (26). 
Briefly, 300 μl of Matrigel (BD Biosciences) was added to the 
wells of a 24-well plate and allowed to polymerize for 20 min 
at 37oC. HUVECs were harvested, resuspended in Medium 
199, and seeded onto Matrigel (0.8 × 105 cells/well). 
Transfection of siRNA and DNA 
HUVECs of 60-80% confluence were transfected with control 
siRNA (Santa Cruz Biotech.; sc-37007) or LDB2 specific siRNA 
(Santa Cruz Biotech.; sc-38023) using Lipofectamine (Invitrogen). 
HUVECs were transfected with plasmid DNAs using Lipo-
fectamine LTX and Plus reagent following manufacturer’s 
instruction (Invitrogen). Total amount of DNA transfected was 
adjusted with the control vector plasmid.
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Morpholino injection
Micro-injections of morpholino oligonucleotides were carried 
out as previously described (26). Briefly, embryos were 
injected at the single-cell stage with 2-5 ng of control 
morpholino (Gene Tools). The sequences for the morpholino 
oligonucleotides used in this study are: ldb2 splicing 
morpholino: 5’-CGTACACACCTGAGAAAGCAGACAT-3’; ldb2 
ATG morpholino: 5’-CATGTTGATTCCGTGTGCCGTTTGC-3’; 
mismatch control for ldb2 ATG morpholino; 5’-CATCTTCA 
TTGCGTCTGCCCTTTGC-3’.
3-D Fibrin gel assay for endothelial sprouting
Endothelial sprouting assays were performed as previously 
described (27) with some modifications. HUVECs were 
trypsinized and mixed with Cytodex microcarrier beads 
(Amersham Pharmacia) at a ratio of 106 cells per 2,500 beads 
for 4 h at 37oC. After incubation for 24 h at 37oC, the coated 
beads were embedded into the fibrinogen with thrombin. The 
clots were overlaid with 2 × 104 human lung carcinoma 
fibroblasts (WI-38) and incubated with 2 ml of EGM-2 medium 
per well. Media was replaced every 2 days and vessel 
formation was analyzed after 3-5 days. 
qRT-PCR
Total RNA was extracted and purified using the RNeasy kit 
(Qiagen). qRT-PCR was performed with 1× SYBR Green Mix 
(Invitrogen) with a Bio-Rad real-time PCR detection system. For 
each reaction, 100 ng of total RNA was transcribed at 50oC for 
followed by a denaturing step at 95oC for 5 min, 40 cycles of 
95oC for 30 s and 60oC for 30 s. Fluorescence data were 
collected and analyzed using an I-cycler (Bio-Rad). For 
normalization, human GAPDH was used as the endogenous 
control.
Western blotting
Cell pellets were lysed on ice with RIPA buffer supplemented 
with phosphatase inhibitor cocktail tablets (Roche) and then 
were mixed with 6× sample buffer. Protein samples were 
electrophoresed by SDS-PAGE and transferred to PVDF 
membranes. The membranes were probed with anti-LDB2 
(1:500, Abcam), anti-DLL4 (1:500, Cell Signaling), and anti- 
β-actin (1:1,000, Santa Cruz) antibodies and detection was 
performed with an ECL Plus detection kit (Amersham 
Bioscience).
Luciferase assay
The luciferase reporter assay was performed as described 
previously (28, 29). HUVECs that were plated onto a gelatin- 
coated dish were transfected with different expression vectors 
along with reporter plasmids as described in the figures. The 
total amount of transfected plasmid DNA was adjusted with 
empty vector DNA. Luciferase activity was assayed 24 h after 
transfection. Cells were lysed with Passive lysis buffer (Promega), 
and luciferase activities in cell extracts were determined 24 h 
after transfection using a Dual luciferase assay system 
(Promega).
CHIP assay
The CHIP assay was performed using a CHIP kit (Millipore) as 
previously described, with some modification (30). Genomic 
DNA and protein were cross-linked by adding formaldehyde 
(1%, final concentration) directly to the culture medium and 
incubating for 10 min at 37oC. Then, the cells were harvested, 
lysed, and sonicated to generate 0.3-1.0 kb DNA fragments. 
After centrifugation, the cleared supernatant was incubated 
with anti-TAL1 (Santa Cruz), anti-GATA2 (Santa Cruz), 
anti-FLAG (Sigma), and IgG for immunoprecipitation. 
Co-immunoprecipitated and input DNAs were amplified by 
PCR, and amplified DNA was separated on a 1.5% agarose gel 
and visualized with ethidium bromide.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 4.0. 
Data are presented as mean ± standard deviation (SD). 
Differences between groups were performed through an 
unpaired Student’s t-test. A value of P ＜ 0.05 was considered 
significant. 
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